MediciNova has received a Notice of Decision to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 – ibudilast – and interferon-beta for the treatment of progressive multiple sclerosis, or MS. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than October 2039.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNOV:
- Biotech Alert: Searches spiking for these stocks today
- MediciNova announces new data, results of Phase 2 trial of MN-166 in GBM
- MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
- MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
- MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
